-
1
-
-
84937174490
-
Pathophysiology of the Alzheímer's syndrome
-
Blass JP. Pathophysiology of the Alzheímer's syndrome. Neurology 1993;43(4 Suppl):25S-38S.
-
(1993)
Neurology
, vol.43
, Issue.4 SUPPL.
-
-
Blass, J.P.1
-
2
-
-
0027761432
-
Neurochemical pathology and therapeutic strategies in degenerative dementia
-
Perry EK, Perry RH. Neurochemical pathology and therapeutic strategies in degenerative dementia. International Review of Psychiatry 1993;5:363-80.
-
(1993)
International Review of Psychiatry
, vol.5
, pp. 363-380
-
-
Perry, E.K.1
Perry, R.H.2
-
3
-
-
0028238408
-
Emerging drugs for Alzheimer's disease: Mechanisms of action and prospects for cognitive enhancing medications
-
Schneider LS, Tariot PN. Emerging drugs for Alzheimer's disease: mechanisms of action and prospects for cognitive enhancing medications. Med Clin North Am 1904;78:911-34.
-
(1904)
Med Clin North Am
, vol.78
, pp. 911-934
-
-
Schneider, L.S.1
Tariot, P.N.2
-
4
-
-
1842283971
-
Neurobiology and treatment of dementia
-
Salzman C, editor. Baltimore: Williams & Wilkins
-
Tariot PN. Neurobiology and treatment of dementia. In: Salzman C, editor. Clinical geriatric psychopharmacology. Baltimore: Williams & Wilkins; 1992. p 277-99.
-
(1992)
Clinical Geriatric Psychopharmacology
, pp. 277-299
-
-
Tariot, P.N.1
-
5
-
-
0029263518
-
Cholinergic therapies for Alzheimer's disease: Palliative or disease altering?
-
Davis RE, Doyle PD, Carroll RT, Emmerling MR, Jaen J. Cholinergic therapies for Alzheimer's disease: palliative or disease altering? Arzneimittel-Forschung 1995;45:425-31.
-
(1995)
Arzneimittel-Forschung
, vol.45
, pp. 425-431
-
-
Davis, R.E.1
Doyle, P.D.2
Carroll, R.T.3
Emmerling, M.R.4
Jaen, J.5
-
6
-
-
0028722665
-
Therapy of Alzheimer disease: Symptomatic or neuroprotective?
-
Giacobini E. Therapy of Alzheimer disease: symptomatic or neuroprotective? J Neural Transm 1994;Suppl 43:211S-2I7S.
-
(1994)
J Neural Transm
, Issue.43 SUPPL.
-
-
Giacobini, E.1
-
7
-
-
0026788495
-
Clinical trials in cognitive impairment in the elderly
-
Forette F, Panisset M, Boller F. Clinical trials in cognitive impairment in the elderly. Aging 1992;4:239-50.
-
(1992)
Aging
, vol.4
, pp. 239-250
-
-
Forette, F.1
Panisset, M.2
Boller, F.3
-
8
-
-
0025377720
-
Keynote lecture 1: Problems in the search for cognitive enhancers
-
Hollister LE. Keynote lecture 1: problems in the search for cognitive enhancers. Pharmacopsychiatry 1990;23(Suppl):33S-36S.
-
(1990)
Pharmacopsychiatry
, vol.23
, Issue.SUPPL.
-
-
Hollister, L.E.1
-
9
-
-
0026708890
-
Proof of efficacy of nootropics for the indication "dementia" (phase III)-recommendations
-
Menges K. Proof of efficacy of nootropics for the indication "dementia" (phase III)-recommendations. Pharmacopsychiatry 1992;25:126-35.
-
(1992)
Pharmacopsychiatry
, vol.25
, pp. 126-135
-
-
Menges, K.1
-
10
-
-
0028852890
-
A preliminary study on plasma concentrations of bifemelane, indeloxazine and propentofylline in aged patients with organic brain disorders
-
Minami M, Arai H, Takahashi T, Kimura M, Noguchi I, Suzuki T, and others. A preliminary study on plasma concentrations of bifemelane, indeloxazine and propentofylline in aged patients with organic brain disorders. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:59-64.
-
(1995)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.19
, pp. 59-64
-
-
Minami, M.1
Arai, H.2
Takahashi, T.3
Kimura, M.4
Noguchi, I.5
Suzuki, T.6
-
11
-
-
0029101130
-
Clinical pharmacokinetics of drugs for Alzheimer's disease
-
Parnetti L. Clinical pharmacokinetics of drugs for Alzheimer's disease. Clin Pharmacokinet 1995;29:110-29.
-
(1995)
Clin Pharmacokinet
, vol.29
, pp. 110-129
-
-
Parnetti, L.1
-
12
-
-
0027941873
-
Memory disorders: Novel treatments, clinical perspective
-
Pepeu G. Memory disorders: novel treatments, clinical perspective. Life Sci 1994;55:2189-94.
-
(1994)
Life Sci
, vol.55
, pp. 2189-2194
-
-
Pepeu, G.1
-
13
-
-
0027058349
-
Neuropsychological factors in mental disorders and their treatments: Measurement and interpretation of changes in memory in response to drug treatment
-
Weingartner H, Eckardt M, Molchan S, Sunderland T, Wolkowitz O. Neuropsychological factors in mental disorders and their treatments: measurement and interpretation of changes in memory in response to drug treatment. Psychopharmacol Bull 1992;28:331-40.
-
(1992)
Psychopharmacol Bull
, vol.28
, pp. 331-340
-
-
Weingartner, H.1
Eckardt, M.2
Molchan, S.3
Sunderland, T.4
Wolkowitz, O.5
-
15
-
-
0028897914
-
Canadian guidelines for the development of antidementia therapies: A conceptual summary
-
Mohr E, Feldman H, Gauthier S. Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can J Neurol Sci 1995;22(1):62-71.
-
(1995)
Can J Neurol Sci
, vol.22
, Issue.1
, pp. 62-71
-
-
Mohr, E.1
Feldman, H.2
Gauthier, S.3
-
19
-
-
0027515763
-
Desferrioxamine and Alzheimer's disease: Video home behavior assessment of clinical course and measures of brain aluminum
-
McLachlan DR, Smith WL, Kruck TP. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum. Ther Drug Monit 1993;15:602-7.
-
(1993)
Ther Drug Monit
, vol.15
, pp. 602-607
-
-
McLachlan, D.R.1
Smith, W.L.2
Kruck, T.P.3
-
20
-
-
0022261647
-
Chelatíon therapy: Unproved modality in the treatment of Alzheimer-type dementia
-
Cardelli MB, Russell M, Bagne CA, Pomara N. Chelatíon therapy: unproved modality in the treatment of Alzheimer-type dementia. J Am Geriatr Soc 1985;33:548-51.
-
(1985)
J Am Geriatr Soc
, vol.33
, pp. 548-551
-
-
Cardelli, M.B.1
Russell, M.2
Bagne, C.A.3
Pomara, N.4
-
21
-
-
0027268393
-
Clinical trial of indomethacin in Alzheimer's disease
-
Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, and others. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
-
(1993)
Neurology
, vol.43
, pp. 1609-1611
-
-
Rogers, J.1
Kirby, L.C.2
Hempelman, S.R.3
Berry, D.L.4
McGeer, P.L.5
Kaszniak, A.W.6
-
22
-
-
0023932737
-
Calcium antagonists and multi-infarct dementia: A trial involving sequential NMR and psychometric assessment
-
Besson JA, Palin AN, Ebmeier KP, Eagles JM, Smith FW. Calcium antagonists and multi-infarct dementia: a trial involving sequential NMR and psychometric assessment. International Journal of Geriatric Psychiatry 1988;3:99-105.
-
(1988)
International Journal of Geriatric Psychiatry
, vol.3
, pp. 99-105
-
-
Besson, J.A.1
Palin, A.N.2
Ebmeier, K.P.3
Eagles, J.M.4
Smith, F.W.5
-
23
-
-
0025102819
-
Nimodipine in the treatment of old age dementias
-
Ban TA, Morey L, Aguglia E, Azzarelli O, Balsano F, Marigliano V, and others. Nimodipine in the treatment of old age dementias. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:525-51.
-
(1990)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.14
, pp. 525-551
-
-
Ban, T.A.1
Morey, L.2
Aguglia, E.3
Azzarelli, O.4
Balsano, F.5
Marigliano, V.6
-
24
-
-
0025320360
-
Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia
-
Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Society of Biological Psychiatry 1990;27:1133-42.
-
(1990)
Society of Biological Psychiatry
, vol.27
, pp. 1133-1142
-
-
Tollefson, G.D.1
-
25
-
-
0025977499
-
Mid-term treatment of dementia with nimodipine: European Congress on Geriatric Treatment (1990, Catania, Italy)
-
Schinco P. Mid-term treatment of dementia with nimodipine: European Congress on Geriatric Treatment (1990, Catania, Italy). Archives of Gerontology & Geriatrics 1991;(2 Suppl):169S-172S.
-
(1991)
Archives of Gerontology & Geriatrics
, Issue.2 SUPPL.
-
-
Schinco, P.1
-
26
-
-
0027135596
-
Divergent neuroprotective effects of nimodipine in PDD and MID provide indirect evidence of disturbances in Ca2+ homeostasis in dementia
-
Fischhof PK. Divergent neuroprotective effects of nimodipine in PDD and MID provide indirect evidence of disturbances in Ca2+ homeostasis in dementia. Methods Find Exp Clin Pharmacol 1993;15:549-55.
-
(1993)
Methods Find Exp Clin Pharmacol
, vol.15
, pp. 549-555
-
-
Fischhof, P.K.1
-
28
-
-
0027327689
-
A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer's disease
-
Sudilovsky A, Cutler NR, Sramek JJ, Wardle T, Veroff AE, Mickelson W, and others. A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer's disease. Alzheimer Dis Assoc Disord 1993;7:105-11.
-
(1993)
Alzheimer Dis Assoc Disord
, vol.7
, pp. 105-111
-
-
Sudilovsky, A.1
Cutler, N.R.2
Sramek, J.J.3
Wardle, T.4
Veroff, A.E.5
Mickelson, W.6
-
29
-
-
0022646038
-
Double-blind randomized controlled study of phosphatidylserine in senile demented patients
-
Delwaide PJ, Gyselynck-Mambourg AM, Hurlet A, Ylieff M. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand 1986;73:136-40.
-
(1986)
Acta Neurol Scand
, vol.73
, pp. 136-140
-
-
Delwaide, P.J.1
Gyselynck-Mambourg, A.M.2
Hurlet, A.3
Ylieff, M.4
-
30
-
-
0023931072
-
Phosphatidylserine in the treatment of Alzheimer's disease: Results of a multicenter study
-
Amaducci L, the SMID Group. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Psychopharmacol Bull 1988;24:130-4.
-
(1988)
Psychopharmacol Bull
, vol.24
, pp. 130-134
-
-
Amaducci, L.1
-
31
-
-
0025030436
-
Selegiline in the treatment of mild to moderate Alzheimer-type dementia
-
Monteverde A, Gnemmi P, Rossi F, Monteverde A, Finali GC. Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 1990;12:315-2.
-
(1990)
Clin Ther
, vol.12
, pp. 315-322
-
-
Monteverde, A.1
Gnemmi, P.2
Rossi, F.3
Monteverde, A.4
Finali, G.C.5
-
33
-
-
0026872682
-
Double-blind cross-over study of phosphatidylserine vs placebo in patients with early dementia of the Alzheimer type
-
Engel RR, Satzger W, Gunther W, Kathmann N, Bove D, Gerke S, and others. Double-blind cross-over study of phosphatidylserine vs placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol 1992;2:149-55.
-
(1992)
Eur Neuropsychopharmacol
, vol.2
, pp. 149-155
-
-
Engel, R.R.1
Satzger, W.2
Gunther, W.3
Kathmann, N.4
Bove, D.5
Gerke, S.6
-
34
-
-
0024149141
-
Multicenter clinical placebo-controlled study with acetyl-1-carnitine (LAC) in the treatment of mildly demented elderly patients
-
Cucínotta D, Passeri M, Ventura S, Iannuccelli M, Senin U, Bonati PA, and others. Multicenter clinical placebo-controlled study with acetyl-1-carnitine (LAC) in the treatment of mildly demented elderly patients. Drug Development Research 1988;14:213-6.
-
(1988)
Drug Development Research
, vol.14
, pp. 213-216
-
-
Cucínotta, D.1
Passeri, M.2
Ventura, S.3
Iannuccelli, M.4
Senin, U.5
Bonati, P.A.6
-
35
-
-
0013625850
-
Peripheral cholinergic changes and pharmacological aspects in Alzheimer's disease
-
Giacobini E, Becker R, editors. New York: Taylor and Francis
-
Ravizza L, Ferrero P, Eva C, Rocca P, Tarenzi L, Benna P. Peripheral cholinergic changes and pharmacological aspects in Alzheimer's disease. In: Giacobini E, Becker R, editors. Current research in Alzheimer therapy. New York: Taylor and Francis; 1988. p 355-63.
-
(1988)
Current Research in Alzheimer Therapy
, pp. 355-363
-
-
Ravizza, L.1
Ferrero, P.2
Eva, C.3
Rocca, P.4
Tarenzi, L.5
Benna, P.6
-
36
-
-
0025032370
-
Selegiline versus 1-acetylcarnitine in the treatment of Alzheimer-type dementia
-
Campi N, Todeschini GP, Scarzella L. Selegiline versus 1-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 1990;12:306-14.
-
(1990)
Clin Ther
, vol.12
, pp. 306-314
-
-
Campi, N.1
Todeschini, G.P.2
Scarzella, L.3
-
37
-
-
0024786493
-
Double-blind, placebo controlled study of acetyl-1-carnitine in patients with Alzheimer's dementia
-
Rai G, Wright G, Scott L, Beston B, Rest J, Exton-Smith AN. Double-blind, placebo controlled study of acetyl-1-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin 1990;11:638-47.
-
(1990)
Curr Med Res Opin
, vol.11
, pp. 638-647
-
-
Rai, G.1
Wright, G.2
Scott, L.3
Beston, B.4
Rest, J.5
Exton-Smith, A.N.6
-
38
-
-
0026460074
-
Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease
-
Sano M, Bell K, Cote L, Dooneief G, Lawton A, Legler L, and others. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 1992;49:1137-41.
-
(1992)
Arch Neurol
, vol.49
, pp. 1137-1141
-
-
Sano, M.1
Bell, K.2
Cote, L.3
Dooneief, G.4
Lawton, A.5
Legler, L.6
-
39
-
-
0026354478
-
Acetyl-1-camitine in dementia
-
Livingston G, Sax KB, McClenahan Z, Blumenthal E, Foley K, Willison J, and others. Acetyl-1-camitine in dementia. International Journal of Geriatric Psychiatry 1991;6:853-60.
-
(1991)
International Journal of Geriatric Psychiatry
, vol.6
, pp. 853-860
-
-
Livingston, G.1
Sax, K.B.2
McClenahan, Z.3
Blumenthal, E.4
Foley, K.5
Willison, J.6
-
40
-
-
0028891690
-
Clinical and neurochemical effects of acetyl-1-carnitine in Alzheimer's disease
-
Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ. Clinical and neurochemical effects of acetyl-1-carnitine in Alzheimer's disease. Neurobiology of Aging 1995;16(1):1-4.
-
(1995)
Neurobiology of Aging
, vol.16
, Issue.1
, pp. 1-4
-
-
Pettegrew, J.W.1
Klunk, W.E.2
Panchalingam, K.3
Kanfer, J.N.4
McClure, R.J.5
-
41
-
-
0028301970
-
Superiority of Antagonic-Stress composition versus nicergoline in gerontopsychiatry
-
Schneider F, Popa R, Mihalas G, Stefaniga P, Míhalas IG, Maties R, and others. Superiority of Antagonic-Stress composition versus nicergoline in gerontopsychiatry. Ann N Y Acad Sci 1994;717:332-42.
-
(1994)
Ann N Y Acad Sci
, vol.717
, pp. 332-342
-
-
Schneider, F.1
Popa, R.2
Mihalas, G.3
Stefaniga, P.4
Míhalas, I.G.5
Maties, R.6
-
42
-
-
0028141762
-
Overview of clinical trials of hydergine in dementia
-
Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol 1994;51:787-98.
-
(1994)
Arch Neurol
, vol.51
, pp. 787-798
-
-
Schneider, L.S.1
Olin, J.T.2
-
43
-
-
0024594024
-
Nicergoline in mild to moderate dementia: A multicenter, double-blind, placebo-controlled study
-
International Symposium on Alzheimer's Disease (1987, Amsterdam, Netherlands)
-
Battaglia A, Bruni G, Ardia A, Sacchetti G. Nicergoline in mild to moderate dementia: a multicenter, double-blind, placebo-controlled study. International Symposium on Alzheimer's Disease (1987, Amsterdam, Netherlands). J Am Gerìatr Soc 1989;37:295-302.
-
(1989)
J Am Gerìatr Soc
, vol.37
, pp. 295-302
-
-
Battaglia, A.1
Bruni, G.2
Ardia, A.3
Sacchetti, G.4
-
44
-
-
0025009025
-
A double-blind randomized study of two ergot derivatives in mild to moderate dementia
-
Battaglia A, Bruni G, Sacchetti G, Pamparana F, Nicergoline Cooperative Study Group. A double-blind randomized study of two ergot derivatives in mild to moderate dementia. Current Therapeutic Research 1990;48:597-612.
-
(1990)
Current Therapeutic Research
, vol.48
, pp. 597-612
-
-
Battaglia, A.1
Bruni, G.2
Sacchetti, G.3
Pamparana, F.4
-
45
-
-
0026556045
-
The clinical efficacy of nicergoline against psychotic symptoms in dementia
-
Yamagami S, Hirayama E, Mui K, Kioka T, Soejima S, Furutsuka D, and others. The clinical efficacy of nicergoline against psychotic symptoms in dementia. Current Therapeutic Research 1992;51:529-35.
-
(1992)
Current Therapeutic Research
, vol.51
, pp. 529-535
-
-
Yamagami, S.1
Hirayama, E.2
Mui, K.3
Kioka, T.4
Soejima, S.5
Furutsuka, D.6
-
46
-
-
0028935334
-
Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: A double-blind, placebo-controlled, clinical and EEG/ERP mapping study
-
Saletu B, Paulus E, Linzmayer L, Anderer P, Semlitsch HV, Grunberger J, and others. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 1995;117:385-95.
-
(1995)
Psychopharmacology
, vol.117
, pp. 385-395
-
-
Saletu, B.1
Paulus, E.2
Linzmayer, L.3
Anderer, P.4
Semlitsch, H.V.5
Grunberger, J.6
-
47
-
-
0015359233
-
The clinical use of piracetam, a new nootropic drug: The treatment of symptoms of senile involutions
-
Stegink AJ. The clinical use of piracetam, a new nootropic drug: the treatment of symptoms of senile involutions. Arzneimittel-Forschung (Drug Research) 1972;22:975-7.
-
(1972)
Arzneimittel-Forschung (Drug Research)
, vol.22
, pp. 975-977
-
-
Stegink, A.J.1
-
49
-
-
0017799197
-
A double-blind investigation of piracetam (Nootropil) versus placebo in the memory of geriatric inpatients
-
Abuzzahab Sr FS, Merwin GE, Zimmermann RL, Sherman MC. A double-blind investigation of piracetam (Nootropil) versus placebo in the memory of geriatric inpatients. Psychopharmacol Bull 1978;14:23-5.
-
(1978)
Psychopharmacol Bull
, vol.14
, pp. 23-25
-
-
Abuzzahab Sr., F.S.1
Merwin, G.E.2
Zimmermann, R.L.3
Sherman, M.C.4
-
51
-
-
84984360979
-
Cholinergic treatment in Alzheimer's disease: Implications for future research
-
Davis KL, Mohs RC, Davis BM, Levy MI, Horvath TB. Rosenberg GS, and others. Cholinergic treatment in Alzheimer's disease: implications for future research. Aging 1982;19:475-81.
-
(1982)
Aging
, vol.19
, pp. 475-481
-
-
Davis, K.L.1
Mohs, R.C.2
Davis, B.M.3
Levy, M.I.4
Horvath, T.B.5
Rosenberg, G.S.6
-
52
-
-
0011924105
-
Pharmacologic treatment of senile dementia: Choline, 1-dopa, piracetam, and choline plus piracetam
-
Ferris SH, Reísberg B, Crook T, Friedman E, Schneck MK, Mir P, and others. Pharmacologic treatment of senile dementia: choline, 1-dopa, piracetam, and choline plus piracetam. Aging 1982;19:475-81.
-
(1982)
Aging
, vol.19
, pp. 475-481
-
-
Ferris, S.H.1
Reísberg, B.2
Crook, T.3
Friedman, E.4
Schneck, M.K.5
Mir, P.6
-
53
-
-
0020448412
-
The effects of Oxiracetam (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam)
-
Itil TM, Menon GN, Bozak M, Songar A. The effects of Oxiracetam (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam). Drug Development Research 1982;2:447-61.
-
(1982)
Drug Development Research
, vol.2
, pp. 447-461
-
-
Itil, T.M.1
Menon, G.N.2
Bozak, M.3
Songar, A.4
-
54
-
-
0020406924
-
Piracetam in the treatment of cognitive impairment in the elderly
-
Reisberg B, Ferris SH, Schneck MK, Corwin J, Mir P, Friedman E, and others. Piracetam in the treatment of cognitive impairment in the elderly. Drug Development Research 1982;2:475-80.
-
(1982)
Drug Development Research
, vol.2
, pp. 475-480
-
-
Reisberg, B.1
Ferris, S.H.2
Schneck, M.K.3
Corwin, J.4
Mir, P.5
Friedman, E.6
-
55
-
-
0020514842
-
Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment
-
Chouínard G, Annable L, Ross-Chouinard A, Olivier M, Fontaine F. Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment. Psychopharmacology 1983;81:100-6.
-
(1983)
Psychopharmacology
, vol.81
, pp. 100-106
-
-
Chouínard, G.1
Annable, L.2
Ross-Chouinard, A.3
Olivier, M.4
Fontaine, F.5
-
56
-
-
0021186748
-
Controlled clinical trial of oxiracetam in the treatment of chronic cerebrovascular insufficiency in the elderly
-
Ferrero E. Controlled clinical trial of oxiracetam in the treatment of chronic cerebrovascular insufficiency in the elderly. Current Therapeutic Research 1984;36:298-308.
-
(1984)
Current Therapeutic Research
, vol.36
, pp. 298-308
-
-
Ferrero, E.1
-
57
-
-
0021857770
-
Haemorheological pattern in initial mental deterioration: Results of a long-term study using piracetam and pentoxifyl-line
-
Parnetti L, Ciuffetti G, Mercuri M, Senin U. Haemorheological pattern in initial mental deterioration: results of a long-term study using piracetam and pentoxifyl-line. Archives of Gerontology & Geriatrics 1985;4:141-55.
-
(1985)
Archives of Gerontology & Geriatrics
, vol.4
, pp. 141-155
-
-
Parnetti, L.1
Ciuffetti, G.2
Mercuri, M.3
Senin, U.4
-
58
-
-
0022273985
-
Clinical evaluation of compounds for the treatment of memory dysfunction
-
Growdon JH, Corkin S, Huff FJ. Clinical evaluation of compounds for the treatment of memory dysfunction. Ann N Y Acad Sci 1985;444:437-49.
-
(1985)
Ann N Y Acad Sci
, vol.444
, pp. 437-449
-
-
Growdon, J.H.1
Corkin, S.2
Huff, F.J.3
-
59
-
-
0022994947
-
Piracetam combined with lecithin in the treatment of Alzheimer's disease
-
Growdon JH, Corkin S, Jacob F, Rosen TJ. Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurology of Aging 1986;7:269-76.
-
(1986)
Neurology of Aging
, vol.7
, pp. 269-276
-
-
Growdon, J.H.1
Corkin, S.2
Jacob, F.3
Rosen, T.J.4
-
60
-
-
0024444333
-
Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia
-
Corona GL, Cucchi ML, Frattini P, Santagostino G, Schinelli S, Romani A, and others. Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia. European Archives of Psychiatry & Neurological Sciences 1989;239(2):79-86.
-
(1989)
European Archives of Psychiatry & Neurological Sciences
, vol.239
, Issue.2
, pp. 79-86
-
-
Corona, G.L.1
Cucchi, M.L.2
Frattini, P.3
Santagostino, G.4
Schinelli, S.5
Romani, A.6
-
61
-
-
0026875343
-
Moving from the question of efficacy to the question of therapeutic relevance: An exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam
-
Herrmann WM, Stephan K. Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam. Int Psychogeriatr 1992;4:25-44.
-
(1992)
Int Psychogeriatr
, vol.4
, pp. 25-44
-
-
Herrmann, W.M.1
Stephan, K.2
-
62
-
-
0027474562
-
Long-term and high-dose piracetam treatment of Alzheimer's disease
-
Croisile B, Trillet M, Fondarai J, Laurent B, Mauguiere F, Billardon M, and others. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology 1993;43:301-5.
-
(1993)
Neurology
, vol.43
, pp. 301-305
-
-
Croisile, B.1
Trillet, M.2
Fondarai, J.3
Laurent, B.4
Mauguiere, F.5
Billardon, M.6
-
63
-
-
0028061383
-
Drug therapy and memory training programs: A double-blind randomized trial of general practice patients with age-assocíated memory impairment
-
Israel L, Melac M, Mílínkevitch D, Dubos G. Drug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-assocíated memory impairment. International Psychogeriatrics 1994; 6:115-70.
-
(1994)
International Psychogeriatrics
, vol.6
, pp. 115-170
-
-
Israel, L.1
Melac, M.2
Mílínkevitch, D.3
Dubos, G.4
-
64
-
-
0028910046
-
Comparison of teníloxazine and piracetam in Alzheimer-type or vascular dementia
-
Aguglia E, Caraceni T, Genitrini S, Falsaperla A, Martucci N, Bonuccelli U, and others. Comparison of teníloxazine and piracetam in Alzheimer-type or vascular dementia. Current Therapeutic Research 1995;56:250-7.
-
(1995)
Current Therapeutic Research
, vol.56
, pp. 250-257
-
-
Aguglia, E.1
Caraceni, T.2
Genitrini, S.3
Falsaperla, A.4
Martucci, N.5
Bonuccelli, U.6
-
65
-
-
0024455491
-
Oxiracetam in the treatment of multi-infarct dementia
-
Baumel B, Eisner L, Karukin M, MacNamara R, Katz RJ, Deveaugh-Geiss J. Oxiracetam in the treatment of multi-infarct dementia. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:673-82.
-
(1989)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.13
, pp. 673-682
-
-
Baumel, B.1
Eisner, L.2
Karukin, M.3
MacNamara, R.4
Katz, R.J.5
Deveaugh-Geiss, J.6
-
67
-
-
0024827752
-
Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: A double-blind, placebo-controlled study
-
Maina G, Fiori L, Torta R, Fagiani MB, Ravizza L, Bonavita E, and others. Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. Neuropsychobiology 1989;21:141-5.
-
(1989)
Neuropsychobiology
, vol.21
, pp. 141-145
-
-
Maina, G.1
Fiori, L.2
Torta, R.3
Fagiani, M.B.4
Ravizza, L.5
Bonavita, E.6
-
68
-
-
0025200627
-
Selegiline versus oxiracetam in patients with Alzheimer-type dementia
-
Falsaperla A, Preti PAM, Oliani C. Selegiline versus oxiracetam in patients with Alzheimer-type dementia. Clin Ther 1990;12:376-84.
-
(1990)
Clin Ther
, vol.12
, pp. 376-384
-
-
Falsaperla, A.1
Preti, P.A.M.2
Oliani, C.3
-
69
-
-
0027049547
-
Effects of ìdebenone ín elderly subjects with cognitive decline: Results of a multicentre clinical trial
-
Bergamasco B, Villardita C, Coppi R. Effects of ìdebenone ín elderly subjects with cognitive decline: results of a multicentre clinical trial. Archives of Gerontology & Geriatrics 1992;15:279-86.
-
(1992)
Archives of Gerontology & Geriatrics
, vol.15
, pp. 279-286
-
-
Bergamasco, B.1
Villardita, C.2
Coppi, R.3
-
70
-
-
0027092666
-
Oxiracetam in the treatment of primary dementia of the Alzheimer's type: A small case series
-
Dager SR, Loebel JP, Claypool K, Case M, Budech CB, Dunner DL. Oxiracetam in the treatment of primary dementia of the Alzheimer's type: a small case series. International Journal of Geriatric Psychiatry 1992;7:905-12.
-
(1992)
International Journal of Geriatric Psychiatry
, vol.7
, pp. 905-912
-
-
Dager, S.R.1
Loebel, J.P.2
Claypool, K.3
Case, M.4
Budech, C.B.5
Dunner, D.L.6
-
71
-
-
0026480978
-
Treatment trial of oxiracetam in Alzheimer's disease
-
Green RC, Goldstein FC, Auchus AP, Presley R, Clark WS, Van Tuyl L, and others. Treatment trial of oxiracetam in Alzheimer's disease. Arch Neurol 1992;49:1135-6.
-
(1992)
Arch Neurol
, vol.49
, pp. 1135-1136
-
-
Green, R.C.1
Goldstein, F.C.2
Auchus, A.P.3
Presley, R.4
Clark, W.S.5
Van Tuyl, L.6
-
72
-
-
0026605434
-
Clinical studies with oxiracetam inpatients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree
-
Villardita C, Grioli S, Lomeo C, Cattaneo C, Parini J. Clinical studies with oxiracetam inpatients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree. Neuropsychobiology 1992;25(1):24-8.
-
(1992)
Neuropsychobiology
, vol.25
, Issue.1
, pp. 24-28
-
-
Villardita, C.1
Grioli, S.2
Lomeo, C.3
Cattaneo, C.4
Parini, J.5
-
73
-
-
0027548555
-
Treatment of cognitive impairment secondary to degenerative dementia: Effectiveness of oxiracetam therapy
-
Rozzini R, Zanetti O, Bianchetti A. Treatment of cognitive impairment secondary to degenerative dementia: effectiveness of oxiracetam therapy. Acta Neurologica 1993;15(1):44-52.
-
(1993)
Acta Neurologica
, vol.15
, Issue.1
, pp. 44-52
-
-
Rozzini, R.1
Zanetti, O.2
Bianchetti, A.3
-
74
-
-
0021678374
-
Effects of aniracetam, a nootropic drug, in senile dementia - A preliminary report
-
Mizuki Y, Yamada M, Kato I, Takada Y, Tsujimaru S, Inanaga K, and others. Effects of aniracetam, a nootropic drug, in senile dementia - a preliminary report. Kurume Med J 1984;31:135-43.
-
(1984)
Kurume Med J
, vol.31
, pp. 135-143
-
-
Mizuki, Y.1
Yamada, M.2
Kato, I.3
Takada, Y.4
Tsujimaru, S.5
Inanaga, K.6
-
75
-
-
0023147444
-
Senile dementia of the Alzheimer type treated with aniracetam: A new nootropic agent
-
Sourander LB, Portin R, Molsa P, Lahdes A, Rinne UK. Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent. Psychopharmacology 1987;91:90-5.
-
(1987)
Psychopharmacology
, vol.91
, pp. 90-95
-
-
Sourander, L.B.1
Portin, R.2
Molsa, P.3
Lahdes, A.4
Rinne, U.K.5
-
76
-
-
0021031061
-
The therapeutic efficacy of pramiracetam in Alzheímer's disease: Preliminary observations
-
Branconnier RJ, Cole JO, Dessain EC, Spera KF, Ghazvinian S, DeVitt D. The therapeutic efficacy of pramiracetam in Alzheímer's disease: preliminary observations. Psychopharmacol Bull 1983;19:726-30.
-
(1983)
Psychopharmacol Bull
, vol.19
, pp. 726-730
-
-
Branconnier, R.J.1
Cole, J.O.2
Dessain, E.C.3
Spera, K.F.4
Ghazvinian, S.5
DeVitt, D.6
-
77
-
-
0025730734
-
Nootropic drugs in Alzheimer's disease: Symptomatic treatment with pramiracetam
-
Claus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN. Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology 1991;41:570-4.
-
(1991)
Neurology
, vol.41
, pp. 570-574
-
-
Claus, J.J.1
Ludwig, C.2
Mohr, E.3
Giuffra, M.4
Blin, J.5
Chase, T.N.6
-
78
-
-
0027157131
-
Responders and non-responders to bifemelane hydrochloride in Alzheimer-type and multi-infarct dementia
-
Shigeta M, Nishikawa Y, Shimìzu M, Usui M, Hyoki K, Kawamuro Y. Responders and non-responders to bifemelane hydrochloride in Alzheimer-type and multi-infarct dementia. Int Clin Psychopharmacol 1993;8:109-14.
-
(1993)
Int Clin Psychopharmacol
, vol.8
, pp. 109-114
-
-
Shigeta, M.1
Nishikawa, Y.2
Shimìzu, M.3
Usui, M.4
Hyoki, K.5
Kawamuro, Y.6
-
79
-
-
0024334912
-
Gerontopsychological studies using NAI ("Nurnberger Alters-Inventar") on patients with organic psychosyndrome (DSM-III, category 1) treated with centrophenoxine in a double blind, comparative, randomized clinical trial
-
Pek G, Fulop T, Zs-Nagy I. Gerontopsychological studies using NAI ("Nurnberger Alters-Inventar") on patients with organic psychosyndrome (DSM-III, category 1) treated with centrophenoxine in a double blind, comparative, randomized clinical trial. Archives of Gerontology & Geriatrics 1989;9:17-30.
-
(1989)
Archives of Gerontology & Geriatrics
, vol.9
, pp. 17-30
-
-
Pek, G.1
Fulop, T.2
Zs-Nagy, I.3
-
80
-
-
0025533420
-
Propentofylline in adult-onset cognitive disorders: Double-blind, placebo-controlled, clinical, psychometric and brain mapping studies
-
Saletu B, Moller HJ, Grunberger J, Deutsch H, Rossner M. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies. Neuropsychobiology 1990;24(4):173-84.
-
(1990)
Neuropsychobiology
, vol.24
, Issue.4
, pp. 173-184
-
-
Saletu, B.1
Moller, H.J.2
Grunberger, J.3
Deutsch, H.4
Rossner, M.5
-
81
-
-
0028236476
-
Placebo-controlled trial of the xanthíne derivative propentofylline in dementia
-
Moller HJ, Maurer I, Saletu B. Placebo-controlled trial of the xanthíne derivative propentofylline in dementia. Pharmacopsychiatry 1994;27:159-65.
-
(1994)
Pharmacopsychiatry
, vol.27
, pp. 159-165
-
-
Moller, H.J.1
Maurer, I.2
Saletu, B.3
-
82
-
-
0025534580
-
Lack of efficacy of vinpocetine in vascular dementia
-
Robertsson B, Wallin A, Nyth AL, Gottfries CG, Blennow K. Lack of efficacy of vinpocetine in vascular dementia. Dementia 1990;1:316-22.
-
(1990)
Dementia
, vol.1
, pp. 316-322
-
-
Robertsson, B.1
Wallin, A.2
Nyth, A.L.3
Gottfries, C.G.4
Blennow, K.5
-
83
-
-
0022538062
-
On the effects of pyritinol on functional deficits of patients with organic mental disorders
-
Hermann WM, Kern U, Rohmel J. On the effects of pyritinol on functional deficits of patients with organic mental disorders. Pharmacopsychiatry 1986;19:378-85.
-
(1986)
Pharmacopsychiatry
, vol.19
, pp. 378-385
-
-
Hermann, W.M.1
Kern, U.2
Rohmel, J.3
-
84
-
-
0024379593
-
Pyritinol treatment of SDAT patients: Evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements
-
Knezevic S, Mubrin Z, Risberg J, Vucinic G, Spilich G, Gubarev N, and others. Pyritinol treatment of SDAT patients: evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements. Int Clin Psychopharmacol 1989;4:25-38.
-
(1989)
Int Clin Psychopharmacol
, vol.4
, pp. 25-38
-
-
Knezevic, S.1
Mubrin, Z.2
Risberg, J.3
Vucinic, G.4
Spilich, G.5
Gubarev, N.6
-
85
-
-
0026499718
-
Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID)
-
Fischhof PK, Saletu B, Ruther E, Litschauer G, Moslinger-Gehmayr R, Herrmann WM. Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID). Neuropsychobiology 1992;26:65-70.
-
(1992)
Neuropsychobiology
, vol.26
, pp. 65-70
-
-
Fischhof, P.K.1
Saletu, B.2
Ruther, E.3
Litschauer, G.4
Moslinger-Gehmayr, R.5
Herrmann, W.M.6
-
86
-
-
0027335645
-
Effects of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects
-
Allain H, Raoul P, Lieury A, LeCoz F, Gandon J. Effects of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther 1993;15:549-58.
-
(1993)
Clin Ther
, vol.15
, pp. 549-558
-
-
Allain, H.1
Raoul, P.2
Lieury, A.3
LeCoz, F.4
Gandon, J.5
-
87
-
-
0026631288
-
Milacemide: A placebo-controlled study in seníle dementia of the Alzheimer type
-
Dysken MW, Mendels J, LeWitt P, Reisberg B, Pomara N, Wood J, and others. Milacemide: a placebo-controlled study in seníle dementia of the Alzheimer type. J Am Geriatr Soc 1992;40:503-6.
-
(1992)
J Am Geriatr Soc
, vol.40
, pp. 503-506
-
-
Dysken, M.W.1
Mendels, J.2
LeWitt, P.3
Reisberg, B.4
Pomara, N.5
Wood, J.6
-
88
-
-
0028048327
-
d-Cycloserine treatment of Alzheimer disease
-
Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM, Chase TN. d-Cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 1994;8:198-205.
-
(1994)
Alzheimer Dis Assoc Disord
, vol.8
, pp. 198-205
-
-
Randolph, C.1
Roberts, J.W.2
Tierney, M.C.3
Bravi, D.4
Mouradian, M.M.5
Chase, T.N.6
-
89
-
-
0019804523
-
Vasopressin treatment of cognitive dysfunction in progressive dementia
-
Weingartner H, Kaye W, Gold P, Smallberg S, Peterson R, Gillin JC, and others. Vasopressin treatment of cognitive dysfunction in progressive dementia. Life Scí 1981;29:2721-6.
-
(1981)
Life Scí
, vol.29
, pp. 2721-2726
-
-
Weingartner, H.1
Kaye, W.2
Gold, P.3
Smallberg, S.4
Peterson, R.5
Gillin, J.C.6
-
90
-
-
0022477413
-
Naxolone and Alzheimer's disease: Cognitive and behavioral effects of a range of doses
-
Tariot PN, Sunderland T, Weingartner H, Murphy DL, Cohen MR, Cohen RM. Naxolone and Alzheimer's disease: cognitive and behavioral effects of a range of doses. Arch Gen Psychiatry 1986;43:727-32.
-
(1986)
Arch Gen Psychiatry
, vol.43
, pp. 727-732
-
-
Tariot, P.N.1
Sunderland, T.2
Weingartner, H.3
Murphy, D.L.4
Cohen, M.R.5
Cohen, R.M.6
-
91
-
-
0024523689
-
Multicenter trial of naloxone in Alzheimer's disease
-
Henderson VW, Roberts E, Wimer C, Bardolph EL, Chui HC, Damasio AR, and others. Multicenter trial of naloxone in Alzheimer's disease. Ann Neurol 1989;25:404-6.
-
(1989)
Ann Neurol
, vol.25
, pp. 404-406
-
-
Henderson, V.W.1
Roberts, E.2
Wimer, C.3
Bardolph, E.L.4
Chui, H.C.5
Damasio, A.R.6
-
92
-
-
0022981338
-
Naltrexone and Alzheimer's disease
-
Serby M, Resnick R, Jordan B, Alder J, Corwin J, Rotrosen JP. Naltrexone and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10:587-90.
-
(1986)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.10
, pp. 587-590
-
-
Serby, M.1
Resnick, R.2
Jordan, B.3
Alder, J.4
Corwin, J.5
Rotrosen, J.P.6
-
93
-
-
0013572641
-
Therapeutic potential of thyrotropin-releasing hormone (TRH) and lecithin co-administration in Alzheimer's disease
-
Lampe TH, Norris J, Risse SC, Owen-Williams E, Keenan T. Therapeutic potential of thyrotropin-releasing hormone (TRH) and lecithin co-administration in Alzheimer's disease [abstract]. Neurobiol Aging 1990;11:346.
-
(1990)
Neurobiol Aging
, vol.11
, pp. 346
-
-
Lampe, T.H.1
Norris, J.2
Risse, S.C.3
Owen-Williams, E.4
Keenan, T.5
-
94
-
-
0027081623
-
The effects of thyrotropin-releasing hormone and scopolamíne in Alzheimer's disease and normal volunteers
-
Molchan SE, Mellow AM, Hill JL, Weingartner H, Martinez R, Vitiello B, and others. The effects of thyrotropin-releasing hormone and scopolamíne in Alzheimer's disease and normal volunteers. Journal of Psychopharmacology 1992;6:489-500.
-
(1992)
Journal of Psychopharmacology
, vol.6
, pp. 489-500
-
-
Molchan, S.E.1
Mellow, A.M.2
Hill, J.L.3
Weingartner, H.4
Martinez, R.5
Vitiello, B.6
-
95
-
-
0022525677
-
Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type
-
Fillit H, Weinreb H, Cholst I, Luine V, McEwen B, Amador R, and others. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986;11:337-45.
-
(1986)
Psychoneuroendocrinology
, vol.11
, pp. 337-345
-
-
Fillit, H.1
Weinreb, H.2
Cholst, I.3
Luine, V.4
McEwen, B.5
Amador, R.6
-
96
-
-
0019363538
-
Physostigmine and arecoline: Effects of intravenous infusions in Alzheimer presenile dementia
-
Christie JE, Shering A, Ferguson J, Glen AIM. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 1981;138:46-50.
-
(1981)
Br J Psychiatry
, vol.138
, pp. 46-50
-
-
Christie, J.E.1
Shering, A.2
Ferguson, J.3
Glen, A.I.M.4
-
97
-
-
0019949485
-
Enhancements of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine
-
Davis KL, Mohs RC. Enhancements of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982; 139:1421-4.
-
(1982)
Am J Psychiatry
, vol.139
, pp. 1421-1424
-
-
Davis, K.L.1
Mohs, R.C.2
-
98
-
-
0021925448
-
Oral physostigmine treatment of patients with Alzheimer's disease
-
Mohs RC, Davis BM, Johns CA, Mathe AA, Greenwald BS, Horvath TB, and others. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985;142:28-33.
-
(1985)
Am J Psychiatry
, vol.142
, pp. 28-33
-
-
Mohs, R.C.1
Davis, B.M.2
Johns, C.A.3
Mathe, A.A.4
Greenwald, B.S.5
Horvath, T.B.6
-
99
-
-
0022230177
-
Efficacy of oral physostigmine in primary degenerative dementia
-
Beller SA, Overall JE, Swann AC. Efficacy of oral physostigmine in primary degenerative dementia. Psychopharmacology 1985;87:147-51.
-
(1985)
Psychopharmacology
, vol.87
, pp. 147-151
-
-
Beller, S.A.1
Overall, J.E.2
Swann, A.C.3
-
100
-
-
0023197078
-
Effects of oral physostigmine in Alzheimer's disease
-
Stern Y, Sano M, Mayeux R. Effects of oral physostigmine in Alzheimer's disease. Ann Neurol 1987;22:306-10.
-
(1987)
Ann Neurol
, vol.22
, pp. 306-310
-
-
Stern, Y.1
Sano, M.2
Mayeux, R.3
-
101
-
-
0023761106
-
Auditory long latency event-related potentials in Alzheimer's disease and multi-infarct dementia
-
Neshige R, Barrett G. Auditory long latency event-related potentials in Alzheimer's disease and multi-infarct dementia. J Neurol Neurosurg Psychiatry 1988;51:1120-5.
-
(1988)
J Neurol Neurosurg Psychiatry
, vol.51
, pp. 1120-1125
-
-
Neshige, R.1
Barrett, G.2
-
102
-
-
0025074779
-
The effect of long-term physostigmine administration in Alzheimer's disease
-
Harrell LE, Callaway R, Morere D, Falgout J. The effect of long-term physostigmine administration in Alzheimer's disease. Neurology 1990;40:1350-4.
-
(1990)
Neurology
, vol.40
, pp. 1350-1354
-
-
Harrell, L.E.1
Callaway, R.2
Morere, D.3
Falgout, J.4
-
103
-
-
0027250902
-
A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease
-
Bierer LM, Aisen PS, Davidson M, Ryan TM, Stem RG, Schmeidler J, and others. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 1993;7:98-104.
-
(1993)
Alzheimer Dis Assoc Disord
, vol.7
, pp. 98-104
-
-
Bierer, L.M.1
Aisen, P.S.2
Davidson, M.3
Ryan, T.M.4
Stem, R.G.5
Schmeidler, J.6
-
104
-
-
0027396643
-
Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease
-
Sano M, Bell K, Marder K, Stricks L, Stern Y, Mayeux R. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease. Clin Neuropharmacol 1993;16(1):61-9.
-
(1993)
Clin Neuropharmacol
, vol.16
, Issue.1
, pp. 61-69
-
-
Sano, M.1
Bell, K.2
Marder, K.3
Stricks, L.4
Stern, Y.5
Mayeux, R.6
-
105
-
-
0028218590
-
Transdermal physostigmine in the treatment of Alzheimer's disease
-
Levy A, Brandeis R, Treves TA, Meshulam Y, Mawassi F, Feiler D, and others. Transdermal physostigmine in the treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord 1994;8:15-21.
-
(1994)
Alzheimer Dis Assoc Disord
, vol.8
, pp. 15-21
-
-
Levy, A.1
Brandeis, R.2
Treves, T.A.3
Meshulam, Y.4
Mawassi, F.5
Feiler, D.6
-
106
-
-
0028807035
-
Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease
-
Asthana S, Greig NH, Hegedus L, Holloway HH, Raffaele KC, Schapiro MB, and others. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 1995;58:299-309.
-
(1995)
Clin Pharmacol Ther
, vol.58
, pp. 299-309
-
-
Asthana, S.1
Greig, N.H.2
Hegedus, L.3
Holloway, H.H.4
Raffaele, K.C.5
Schapiro, M.B.6
-
107
-
-
0020032644
-
Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia
-
Caltagìrone C, Gainotti G, Masulo C. Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia. Int J Neurosci 1982;16:247-9.
-
(1982)
Int J Neurosci
, vol.16
, pp. 247-249
-
-
Caltagìrone, C.1
Gainotti, G.2
Masulo, C.3
-
108
-
-
0028284299
-
Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy
-
Litvan I, Blesa R, Clark K, Nichelli P, Atack JR, Mouradian MM, and others. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol 1994;36:55-61.
-
(1994)
Ann Neurol
, vol.36
, pp. 55-61
-
-
Litvan, I.1
Blesa, R.2
Clark, K.3
Nichelli, P.4
Atack, J.R.5
Mouradian, M.M.6
-
109
-
-
0028787077
-
1-Deprenyl and physostigmine for the treatment of Alzheimer's disease
-
Marin DB, Bierer LM, Lawlor BA, Ryan TM, Jacobson R, Schmeidler J, and others. 1-Deprenyl and physostigmine for the treatment of Alzheimer's disease. Psychiatry Res 1995;58(3):181-9.
-
(1995)
Psychiatry Res
, vol.58
, Issue.3
, pp. 181-189
-
-
Marin, D.B.1
Bierer, L.M.2
Lawlor, B.A.3
Ryan, T.M.4
Jacobson, R.5
Schmeidler, J.6
-
110
-
-
0028316959
-
Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease
-
Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
-
(1994)
JAMA
, vol.271
, pp. 992-998
-
-
Watkins, P.B.1
Zimmerman, H.J.2
Knapp, M.J.3
Gracon, S.I.4
Lewis, K.W.5
-
111
-
-
0030449513
-
Bíoavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease
-
Lou G, Montgomery PR, Sitar DS. Bíoavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease. J Psychiatry Neurosci 1996;21:334-9.
-
(1996)
J Psychiatry Neurosci
, vol.21
, pp. 334-339
-
-
Lou, G.1
Montgomery, P.R.2
Sitar, D.S.3
-
112
-
-
0022899577
-
Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type
-
Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315:1241-5.
-
(1986)
N Engl J Med
, vol.315
, pp. 1241-1245
-
-
Summers, W.K.1
Majovski, L.V.2
Marsh, G.M.3
Tachiki, K.4
Kling, A.5
-
113
-
-
0025247740
-
Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: A multicentre trial
-
Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. BMJ 1990;300:495-9.
-
(1990)
BMJ
, vol.300
, pp. 495-499
-
-
Chatellier, G.1
Lacomblez, L.2
-
114
-
-
0025312142
-
Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease
-
Gauthier S, Bouchard R, Lamontagne A, Bailey P, Bergman H, Ratner J, and others. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. N Engl J Med 1990;322:1272-6.
-
(1990)
N Engl J Med
, vol.322
, pp. 1272-1276
-
-
Gauthier, S.1
Bouchard, R.2
Lamontagne, A.3
Bailey, P.4
Bergman, H.5
Ratner, J.6
-
116
-
-
0026756286
-
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease
-
Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, and others. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-9.
-
(1992)
N Engl J Med
, vol.327
, pp. 1253-1259
-
-
Davis, K.L.1
Thal, L.J.2
Gamzu, E.R.3
Davis, C.S.4
Woolson, R.F.5
Gracon, S.I.6
-
117
-
-
0026792979
-
A controlled trial of tacrine in Alzheimer's disease
-
Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, and others. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-9.
-
(1992)
JAMA
, vol.268
, pp. 2523-2529
-
-
Farlow, M.1
Gracon, S.I.2
Hershey, L.A.3
Lewis, K.W.4
Sadowsky, C.H.5
Dolan-Ureno, J.6
-
118
-
-
0027512824
-
Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG
-
Mìnthon L, Gustafson L, Dalfelt G, Hagberg B, Nilsson K, Risberg J, and others. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 1993;4:32-42.
-
(1993)
Dementia
, vol.4
, pp. 32-42
-
-
Mìnthon, L.1
Gustafson, L.2
Dalfelt, G.3
Hagberg, B.4
Nilsson, K.5
Risberg, J.6
-
119
-
-
0027719699
-
Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy
-
Alhainen K, Riekkinen PJ Sr. Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scand 1993; Suppl 149:16S-21S.
-
(1993)
Acta Neurol Scand
, Issue.149 SUPPL.
-
-
Alhainen, K.1
Riekkinen Sr., P.J.2
-
120
-
-
0027214653
-
An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease
-
Wilcock GK, Surmon DJ, Scott M, Boyle M, Mulligan K, Neubauer KA, and others. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. Age Ageing 1993;22:316-24.
-
(1993)
Age Ageing
, vol.22
, pp. 316-324
-
-
Wilcock, G.K.1
Surmon, D.J.2
Scott, M.3
Boyle, M.4
Mulligan, K.5
Neubauer, K.A.6
-
121
-
-
0028270519
-
A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
-
Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
-
(1994)
JAMA
, vol.271
, pp. 985-991
-
-
Knapp, M.J.1
Knopman, D.S.2
Solomon, P.R.3
Pendlebury, W.W.4
Davis, C.S.5
Gracon, S.I.6
-
122
-
-
0028175439
-
Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: Double blind trial
-
Maltby N, Broe GA, Creasey H, Jorm AF, Christensen H, Brooks WS. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial. BMJ 1994;308:879-83.
-
(1994)
BMJ
, vol.308
, pp. 879-883
-
-
Maltby, N.1
Broe, G.A.2
Creasey, H.3
Jorm, A.F.4
Christensen, H.5
Brooks, W.S.6
-
123
-
-
0030035653
-
Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
-
Knopman D, Schneider L, Davis K, Talwalker, Smith F, Hoover T, and others. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996;47:166-77.
-
(1996)
Neurology
, vol.47
, pp. 166-177
-
-
Knopman, D.1
Schneider, L.2
Davis, K.3
Talwalker4
Smith, F.5
Hoover, T.6
-
124
-
-
0027165554
-
The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease
-
Alhainen K, Helkala EL, Reinikainen K, Riekkinen P Sr. The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1993;5:185-92.
-
(1993)
J Neural Transm Park Dis Dement Sect
, vol.5
, pp. 185-192
-
-
Alhainen, K.1
Helkala, E.L.2
Reinikainen, K.3
Riekkinen Sr., P.4
-
125
-
-
0026687684
-
Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease
-
Ebmeier KP, Hunter R, Curran SM, Dougal NJ, Murray CL, Wyper DJ, and others. Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. Psychopharmacology 1992;108:103-9.
-
(1992)
Psychopharmacology
, vol.108
, pp. 103-109
-
-
Kp, E.1
Hunter, R.2
Curran, S.M.3
Dougal, N.J.4
Murray, C.L.5
Wyper, D.J.6
-
126
-
-
0029143531
-
Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled study
-
Antuono PG and the Mentane Study Group. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled study. Arch Intern Med 1995;155:1766-72.
-
(1995)
Arch Intern Med
, vol.155
, pp. 1766-1772
-
-
Antuono, P.G.1
-
127
-
-
0029924782
-
Double-blind placebo-controlled study of velnacrine in Alzheimer's disease
-
Zemlan FP, Keys M, Richter RW, Strub RL. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease. Life Sci 1996;58:1823-32.
-
(1996)
Life Sci
, vol.58
, pp. 1823-1832
-
-
Zemlan, F.P.1
Keys, M.2
Richter, R.W.3
Strub, R.L.4
-
128
-
-
10244259208
-
The efficacy and safety of Donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
-
Rogers SL, Friedhoff LT, and the Donepezil Study Group. The efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
-
(1996)
Dementia
, vol.7
, pp. 293-303
-
-
Rogers, S.L.1
Friedhoff, L.T.2
-
129
-
-
0027563450
-
Multicentre study of 1-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type
-
Parnetti L, Abate G, Bartorelli L, Cucinotta D, Cuzzupoli M, Maggioni M, and others. Multicentre study of 1-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type. Drugs & Aging 1993;3:159-64.
-
(1993)
Drugs & Aging
, vol.3
, pp. 159-164
-
-
Parnetti, L.1
Abate, G.2
Bartorelli, L.3
Cucinotta, D.4
Cuzzupoli, M.5
Maggioni, M.6
-
130
-
-
0021242464
-
Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease
-
Smith RC, Vroulis G, Johnson R, Morgan R. Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease. Psychopharmacol Bull 1984;20:542-5.
-
(1984)
Psychopharmacol Bull
, vol.20
, pp. 542-545
-
-
Smith, R.C.1
Vroulis, G.2
Johnson, R.3
Morgan, R.4
-
131
-
-
0028351522
-
Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease
-
Caamano J, Gomez MJ, Franco A, Cacabelos R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease. Methods Find Exp Clin Pharmacol 1994;16:211-8.
-
(1994)
Methods Find Exp Clin Pharmacol
, vol.16
, pp. 211-218
-
-
Caamano, J.1
Gomez, M.J.2
Franco, A.3
Cacabelos, R.4
-
132
-
-
0023177967
-
Induction of depression with oxotremorine in patients with Alzheimer's disease
-
Davis KL, Hollander E, Davidson M, Davis BM, Mohs RC, Horvath TB. Induction of depression with oxotremorine in patients with Alzheimer's disease. Am J Psychiatry 1987;144:468-71.
-
(1987)
Am J Psychiatry
, vol.144
, pp. 468-471
-
-
Davis, K.L.1
Hollander, E.2
Davidson, M.3
Davis, B.M.4
Mohs, R.C.5
Horvath, T.B.6
-
133
-
-
0023780559
-
Multiple-dose arecoline infusions in Alzheimer's disease
-
Tariot PN, Cohen RM, Welkowitz JA, Sunderland T, Newhouse PA, Murphy DL, and others. Multiple-dose arecoline infusions in Alzheimer's disease. Arch Gen Psychiatry 1988;45:901-5.
-
(1988)
Arch Gen Psychiatry
, vol.45
, pp. 901-905
-
-
Tariot, P.N.1
Cohen, R.M.2
Welkowitz, J.A.3
Sunderland, T.4
Newhouse, P.A.5
Murphy, D.L.6
-
134
-
-
0023261008
-
RS 86 in the treatment of Alzheimer's disease: Cognitive and biological effects
-
Hollander E, Davidson M, Mohs RC, Horvath TB, Davis BM, Zemishlany Z, and others. RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol Psychiatry 1987;22:1067-78.
-
(1987)
Biol Psychiatry
, vol.22
, pp. 1067-1078
-
-
Hollander, E.1
Davidson, M.2
Mohs, R.C.3
Horvath, T.B.4
Davis, B.M.5
Zemishlany, Z.6
-
135
-
-
0022628875
-
Muscarinic agonist therapy of Alzheimer's disease: A clinical trial of RS-86
-
Bruno G, Mohr E, Gillespie M, Fedio P, Chase TN. Muscarinic agonist therapy of Alzheimer's disease: a clinical trial of RS-86. Arch Neurol 1986;43:659-61.
-
(1986)
Arch Neurol
, vol.43
, pp. 659-661
-
-
Bruno, G.1
Mohr, E.2
Gillespie, M.3
Fedio, P.4
Chase, T.N.5
-
136
-
-
0028937797
-
Linopirdine: A depolarization-activated releaser of transmitters for treatment of dementia
-
Tarn SW, Zaczek R. Linopirdine: a depolarization-activated releaser of transmitters for treatment of dementia. Adv Exp Med Biol 1995;363:47-56.
-
(1995)
Adv Exp Med Biol
, vol.363
, pp. 47-56
-
-
Tarn, S.W.1
Zaczek, R.2
-
137
-
-
0029073717
-
Posatirelin for the treatment of late-onset Alzheimer's disease: A double-blind multicentre study vs citicoline and ascorbic acid
-
Parnetti L, Ambrosoli L, Abate G, Azzini C, Balestreri R, Bartorelli L, and others. Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid. Acta Neurol Scand 1995;92:135-40.
-
(1995)
Acta Neurol Scand
, vol.92
, pp. 135-140
-
-
Parnetti, L.1
Ambrosoli, L.2
Abate, G.3
Azzini, C.4
Balestreri, R.5
Bartorelli, L.6
-
138
-
-
0029962164
-
Preliminary evaluation of besipirdine for the treatment of Alzheimer's disease
-
Huff FJ and the Besipirdine Study Group. Preliminary evaluation of besipirdine for the treatment of Alzheimer's disease. Ann N Y Acad Sci 1996;777:410-4.
-
(1996)
Ann N Y Acad Sci
, vol.777
, pp. 410-414
-
-
Huff, F.J.1
-
139
-
-
0023109435
-
Cognitive effects of 1-deprenyl in Alzheimer's disease
-
Tariot PN, Sunderland T, Weingartner H, Murphy DL, Welkowitz JA, Thompson K, and others. Cognitive effects of 1-deprenyl in Alzheimer's disease. Psychopharmacology 1987;91:489-95.
-
(1987)
Psychopharmacology
, vol.91
, pp. 489-495
-
-
Tariot, P.N.1
Sunderland, T.2
Weingartner, H.3
Murphy, D.L.4
Welkowitz, J.A.5
Thompson, K.6
-
140
-
-
0025304847
-
Neuropsychological effects of 1-deprenyl in Alzheimer's type dementia
-
Piccinin GL, Finali G, Massimo P. Neuropsychological effects of 1-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol 1990;13:147-63.
-
(1990)
Clin Neuropharmacol
, vol.13
, pp. 147-163
-
-
Piccinin, G.L.1
Finali, G.2
Massimo, P.3
-
142
-
-
0027418345
-
1-Deprenyl in the treatment of mild dementia of the Alzheimer type: Preliminary results
-
Burke WJ, Ranno AE, Roccaforte WH, Wengel SP, Bayer BL, Willcockson NK, and others, 1-Deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results. J Am Geriatr Soc 1993;41:367-70.
-
(1993)
J Am Geriatr Soc
, vol.41
, pp. 367-370
-
-
Burke, W.J.1
Ranno, A.E.2
Roccaforte, W.H.3
Wengel, S.P.4
Bayer, B.L.5
Willcockson, N.K.6
-
143
-
-
0024515651
-
Clonidine treatment of Alzheimer's disease
-
Mohr E, Schlegel J, Fabbrini G, Williams J, Mouradian M, Mann UM, and others. Clonidine treatment of Alzheimer's disease. Arch Neurol 1989;46:376-8.
-
(1989)
Arch Neurol
, vol.46
, pp. 376-378
-
-
Mohr, E.1
Schlegel, J.2
Fabbrini, G.3
Williams, J.4
Mouradian, M.5
Mann, U.M.6
-
144
-
-
0024544145
-
Guanfacine treatment of Alzheimer's disease
-
Schlegel J, Mohr E, Williams J, Mann U, Gearing M, Chase TN. Guanfacine treatment of Alzheimer's disease. Clin Neuropharmacol 1989;12:124-8.
-
(1989)
Clin Neuropharmacol
, vol.12
, pp. 124-128
-
-
Schlegel, J.1
Mohr, E.2
Williams, J.3
Mann, U.4
Gearing, M.5
Chase, T.N.6
-
146
-
-
0027493889
-
Fluvoxamine treatment of dementia: Tryptophan levels
-
Jorgenson S, Bille A, Andersen J, Jensen HV, Olafsson K, Arup P, and others. Fluvoxamine treatment of dementia: tryptophan levels. Biol Psychiatry 1993;34:587-8.
-
(1993)
Biol Psychiatry
, vol.34
, pp. 587-588
-
-
Jorgenson, S.1
Bille, A.2
Andersen, J.3
Jensen, H.V.4
Olafsson, K.5
Arup, P.6
-
147
-
-
0021744670
-
Lack of effect of tryptophan treatment in demented gerontopsychiatric patients
-
Smith DF, Stromgren E, Petersen HN, Williams DG, Sheldon W. Lack of effect of tryptophan treatment in demented gerontopsychiatric patients. Acta Psychiatr Scand 1984;70:470-7.
-
(1984)
Acta Psychiatr Scand
, vol.70
, pp. 470-477
-
-
Smith, D.F.1
Stromgren, E.2
Petersen, H.N.3
Williams, D.G.4
Sheldon, W.5
-
148
-
-
0021955314
-
A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia
-
Dehlin O, Hedenrud B, Jansson P, Norgard J. A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia. Acta Psychiatr Scand 1985;71:190-6.
-
(1985)
Acta Psychiatr Scand
, vol.71
, pp. 190-196
-
-
Dehlin, O.1
Hedenrud, B.2
Jansson, P.3
Norgard, J.4
-
149
-
-
0020674622
-
Lecithin and piracetam in Alzheimer's disease
-
Serby M, Corwin J, Rotrosen J, Ferris SH, Reisberg B, Friedman E, and others. Lecithin and piracetam in Alzheimer's disease. Psychopharmacol Bull 1983;19:126-9.
-
(1983)
Psychopharmacol Bull
, vol.19
, pp. 126-129
-
-
Serby, M.1
Corwin, J.2
Rotrosen, J.3
Ferris, S.H.4
Reisberg, B.5
Friedman, E.6
-
150
-
-
0021675298
-
Treatment of dementia with high doses of lecithin and piracetam
-
Kazdova E, Bohac O, Dolezal V, Faber J, Slanska J, Tucek S. Treatment of dementia with high doses of lecithin and piracetam. Activitas Nervosa Superior 1984;26:244-5.
-
(1984)
Activitas Nervosa Superior
, vol.26
, pp. 244-245
-
-
Kazdova, E.1
Bohac, O.2
Dolezal, V.3
Faber, J.4
Slanska, J.5
Tucek, S.6
-
151
-
-
0021338328
-
Combined piracetam and cholinergic precursor treatment for primary degenerative dementia
-
Pomara N, Block R, Moore N, Rhiew HB, Berchou R, Stanley M, and others. Combined piracetam and cholinergic precursor treatment for primary degenerative dementia. IRCS Medical Science 1984;12:388-9.
-
(1984)
IRCS Medical Science
, vol.12
, pp. 388-389
-
-
Pomara, N.1
Block, R.2
Moore, N.3
Rhiew, H.B.4
Berchou, R.5
Stanley, M.6
-
152
-
-
0027406164
-
A double-blind crossover pilot study of 1-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease
-
Schneider LS, Olin JT, Pawluczyk S. A double-blind crossover pilot study of 1-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Am J Psychiatry 1993;150:321-3.
-
(1993)
Am J Psychiatry
, vol.150
, pp. 321-323
-
-
Schneider, L.S.1
Olin, J.T.2
Pawluczyk, S.3
-
153
-
-
0023018088
-
Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease
-
Thal LJ, Masur DM, Sharpless NS, Fuld PA, Davíes P. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1986;10:627-36.
-
(1986)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.10
, pp. 627-636
-
-
Thal, L.J.1
Masur, D.M.2
Sharpless, N.S.3
Fuld, P.A.4
Davíes, P.5
-
154
-
-
0029886801
-
Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease
-
Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46:1580-4.
-
(1996)
Neurology
, vol.46
, pp. 1580-1584
-
-
Schneider, L.S.1
Farlow, M.R.2
Henderson, V.W.3
Pogoda, J.M.4
-
156
-
-
0027745626
-
NGF and the treatment of Alzheimer's disease
-
Olson L. NGF and the treatment of Alzheimer's disease. Exp Neurol 1993;124:5-15.
-
(1993)
Exp Neurol
, vol.124
, pp. 5-15
-
-
Olson, L.1
-
157
-
-
0029904388
-
Neurotrophins and Alzheìmer's disease: Beyond the cholinergic neurons
-
Knusel B, Gao H. Neurotrophins and Alzheìmer's disease: beyond the cholinergic neurons. Life Sci 1996;58:2019-27.
-
(1996)
Life Sci
, vol.58
, pp. 2019-2027
-
-
Knusel, B.1
Gao, H.2
-
158
-
-
0001867754
-
Conventional pharmacologic treatment for patients with Alzheimer's disease
-
Gottlieb GL, Kumar A. Conventional pharmacologic treatment for patients with Alzheimer's disease. Neurology 1993;43(4 Suppl):56S-63S.
-
(1993)
Neurology
, vol.43
, Issue.4 SUPPL.
-
-
Gottlieb, G.L.1
Kumar, A.2
-
160
-
-
0026403940
-
Acetyl-1-carnitine: A drug able to slow the progress of Alzheimer's disease?
-
Carta A, Calvani M. Acetyl-1-carnitine: a drug able to slow the progress of Alzheimer's disease? Ann N Y Acad Sci 1991;640:228-32.
-
(1991)
Ann N Y Acad Sci
, vol.640
, pp. 228-232
-
-
Carta, A.1
Calvani, M.2
-
161
-
-
0007550585
-
Pharmacological management and treatment of dementia and secondary symptoms
-
Weiner MF, editor. Washington (DC): American Psychiatric Press
-
Weiner MF, Debus JR, Goodkin K, Pharmacological management and treatment of dementia and secondary symptoms. In: Weiner MF, editor. The dementias: diagnosis and management. Washington (DC): American Psychiatric Press; 1991. p 135-66.
-
(1991)
The Dementias: Diagnosis and Management
, pp. 135-166
-
-
Weiner, M.F.1
Debus, J.R.2
Goodkin, K.3
-
162
-
-
0027151789
-
Clinical aspects of nimodipine
-
18th CINP Congress Satellite Symposium: Calcium homeostasis and brain function: pharmacological rationale and clinical implications (1992, Nice, France)
-
Grobe-Einsler R. Clinical aspects of nimodipine. 18th CINP Congress Satellite Symposium: Calcium homeostasis and brain function: pharmacological rationale and clinical implications (1992, Nice, France), Clin Neuropharmacol 1993; 16(1 Suppl):39S-45S.
-
(1993)
Clin Neuropharmacol
, vol.16
, Issue.1 SUPPL.
-
-
Grobe-Einsler, R.1
-
163
-
-
0026481585
-
Global rating, symptoms, behavior, and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes
-
Schmage N, Bergener M. Global rating, symptoms, behavior, and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes. Int Psychogeriatr 1992; 4(1 Suppl):89S-99S.
-
(1992)
Int Psychogeriatr
, vol.4
, Issue.1 SUPPL.
-
-
Schmage, N.1
Bergener, M.2
-
164
-
-
0028874179
-
Therapeutic approaches for memory impairments
-
Hock FJ. Therapeutic approaches for memory impairments. Behav Brain Res 1995;66:143-50.
-
(1995)
Behav Brain Res
, vol.66
, pp. 143-150
-
-
Hock, F.J.1
-
166
-
-
0020558130
-
The efficacy of the cerebral metabolic enhancers in the treatment of senile dementia
-
Branconnier RJ. The efficacy of the cerebral metabolic enhancers in the treatment of senile dementia. Psychopharmacol Bull 1983;19:212-9.
-
(1983)
Psychopharmacol Bull
, vol.19
, pp. 212-219
-
-
Branconnier, R.J.1
-
167
-
-
25844485515
-
Nootropics
-
Reisberg R, editor. New York: Free Press
-
Schneck MK. Nootropics, In: Reisberg R, editor. Nootropics in Alzheimer's disease. New York: Free Press; 1983. p 362-8.
-
(1983)
Nootropics in Alzheimer's Disease
, pp. 362-368
-
-
Schneck, M.K.1
-
168
-
-
0020629538
-
"Cerebroactive" drugs: Clinical pharmacology and therapeutic role in cerebrovascular disorders
-
Spagnoli A, Tognoni G. "Cerebroactive" drugs: clinical pharmacology and therapeutic role in cerebrovascular disorders. Drugs 1983;26:44-69.
-
(1983)
Drugs
, vol.26
, pp. 44-69
-
-
Spagnoli, A.1
Tognoni, G.2
-
169
-
-
1842404583
-
Nootropic rugs in dementia: Preclinical prospects and clinical lessons
-
Katz RJ. Nootropic rugs in dementia: preclinical prospects and clinical lessons. Animal Models in Psychiatric Disorders 1988;1:175-88.
-
(1988)
Animal Models in Psychiatric Disorders
, vol.1
, pp. 175-188
-
-
Katz, R.J.1
-
170
-
-
0025332303
-
Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia
-
Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 1990;101:147-59.
-
(1990)
Psychopharmacology
, vol.101
, pp. 147-159
-
-
Nicholson, C.D.1
-
171
-
-
0025718364
-
Piracetam: An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders
-
Vernon MW, Sorkin EM. Piracetam: an overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs & Aging 1991;1:17-35.
-
(1991)
Drugs & Aging
, vol.1
, pp. 17-35
-
-
Vernon, M.W.1
Sorkin, E.M.2
-
172
-
-
0026093863
-
Multi-infarct dementia: Prevention and treatment
-
Wade JPH. Multi-infarct dementia: prevention and treatment. Alzheimer Dis Assoc Disord 1991;5:144-8.
-
(1991)
Alzheimer Dis Assoc Disord
, vol.5
, pp. 144-148
-
-
Wade, J.P.H.1
-
174
-
-
0017170501
-
An ergot alkaloid preparation (Hydergine) in the treatment of dementia: Critical review of the clinical literature
-
Hughes JR, Williams JG, Currier RD. An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature. J Am Geriatr Soc 1976;24;490-7.
-
(1976)
J Am Geriatr Soc
, vol.24
, pp. 490-497
-
-
Hughes, J.R.1
Williams, J.G.2
Currier, R.D.3
-
175
-
-
0018712497
-
Hydergine: A review of 26 clinical studies
-
McDonald RJ. Hydergine: a review of 26 clinical studies. Pharmacopsychiatry 1979;12:407-22.
-
(1979)
Pharmacopsychiatry
, vol.12
, pp. 407-422
-
-
McDonald, R.J.1
-
176
-
-
0029875457
-
HWa 285 (propentofylline) - A new compound for the treatment of both vascular dementia and dementia of the Alzheimer type
-
Rother M, Kittner B, Rudolph K, Robner M, Labs KH. HWA 285 (propentofylline) - a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type. Ann N Y Acad Sci 1996;777:404-9.
-
(1996)
Ann N Y Acad Sci
, vol.777
, pp. 404-409
-
-
Rother, M.1
Kittner, B.2
Rudolph, K.3
Robner, M.4
Labs, K.H.5
-
177
-
-
0026408120
-
Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia
-
Herting RL. Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia. Ann N Y Acad Sci 1991;640:237-40.
-
(1991)
Ann N Y Acad Sci
, vol.640
, pp. 237-240
-
-
Herting, R.L.1
-
178
-
-
0019972810
-
The cholinergic hypothesis of geriatric memory dysfunction
-
Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-17.
-
(1982)
Science
, vol.217
, pp. 408-417
-
-
Bartus, R.T.1
Dean III, R.L.2
Beer, B.3
Lippa, A.S.4
-
179
-
-
0026702524
-
The implication of current therapeutic approaches for the cholinergic hypothesis of dementia
-
Traub M, Freedman SB. The implication of current therapeutic approaches for the cholinergic hypothesis of dementia. Dementia 1992;3:189-92.
-
(1992)
Dementia
, vol.3
, pp. 189-192
-
-
Traub, M.1
Freedman, S.B.2
-
180
-
-
0027240047
-
New Alzheimer's drug expands your options in symptom management
-
Wolf-Klein GP. New Alzheimer's drug expands your options in symptom management. Geriatrics 1993;48(8):26-9.
-
(1993)
Geriatrics
, vol.48
, Issue.8
, pp. 26-29
-
-
Wolf-Klein, G.P.1
-
181
-
-
0028448282
-
Tacrine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease
-
Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs & Aging 1994;4:510-40.
-
(1994)
Drugs & Aging
, vol.4
, pp. 510-540
-
-
Wagstaff, A.J.1
McTavish, D.2
-
182
-
-
0029160650
-
Therapeutic trials in Alzheimer's disease
-
Whitehouse PJ, Voci J. Therapeutic trials in Alzheimer's disease. Curr Opin Neurol 1995;8:275-8.
-
(1995)
Curr Opin Neurol
, vol.8
, pp. 275-278
-
-
Whitehouse, P.J.1
Voci, J.2
-
183
-
-
0028198828
-
Tacrine: First drug approved for Alzheimer's disease
-
Crismon ML. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 1994;28:744-51.
-
(1994)
Ann Pharmacother
, vol.28
, pp. 744-751
-
-
Crismon, M.L.1
-
184
-
-
0027969027
-
Tacrine therapy for the dementia of Alzheimer's disease
-
Manning FC. Tacrine therapy for the dementia of Alzheimer's disease. Am Fam Physician 1994;50:819-26.
-
(1994)
Am Fam Physician
, vol.50
, pp. 819-826
-
-
Manning, F.C.1
-
185
-
-
0029013785
-
THA-historical aspects, review of pharmacological properties and therapeutic effects
-
Soares JC, Gershon S. THA-historical aspects, review of pharmacological properties and therapeutic effects. Dementia 1995;6:225-34.
-
(1995)
Dementia
, vol.6
, pp. 225-234
-
-
Soares, J.C.1
Gershon, S.2
-
186
-
-
0027748339
-
Pharmacodynamic and early clinical studies with velnacrine
-
Siegfried KR. Pharmacodynamic and early clinical studies with velnacrine. Acta Neurol Scand 1993;149(9 Suppl):26S-28S.
-
(1993)
Acta Neurol Scand
, vol.149
, Issue.9 SUPPL.
-
-
Siegfried, K.R.1
-
187
-
-
0028590052
-
Therapy with 1-deprenyl (selegilíne) and relation to abuse liability
-
Schneider LS, Tariot PN, Goldstein B. Therapy with 1-deprenyl (selegilíne) and relation to abuse liability. Clin Pharmacol Ther 1994;56:750-6.
-
(1994)
Clin Pharmacol Ther
, vol.56
, pp. 750-756
-
-
Schneider, L.S.1
Tariot, P.N.2
Goldstein, B.3
-
188
-
-
0027323369
-
Noradrenergic modulation of cognitive function: Clinical implications of anatomical, electrophysiological and behavioural studies in animal models
-
Berridge CW, Arnsten AF, Foote SL. Noradrenergic modulation of cognitive function: clinical implications of anatomical, electrophysiological and behavioural studies in animal models. Psychol Med 1993;23:557-64.
-
(1993)
Psychol Med
, vol.23
, pp. 557-564
-
-
Berridge, C.W.1
Arnsten, A.F.2
Foote, S.L.3
-
189
-
-
0029086845
-
Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia
-
Muller WE, Mutschler E, Riederer P. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry 1995;28:113-24.
-
(1995)
Pharmacopsychiatry
, vol.28
, pp. 113-124
-
-
Muller, W.E.1
Mutschler, E.2
Riederer, P.3
|